Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy.


Journal

International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237

Informations de publication

Date de publication:
03 2019
Historique:
received: 10 08 2017
accepted: 14 10 2018
pubmed: 28 12 2018
medline: 17 6 2020
entrez: 28 12 2018
Statut: ppublish

Résumé

To determine the long-term oncological outcome of organ-confined (<pT3) renal cell carcinoma. We identified 889 patients with complete long-term follow-up data, who had been surgically treated for renal cell carcinoma (<T3) at our institution between 1976 and 2009. Kaplan-Meier analysis was used to assess the incidence and time interval of recurrence defined as local recurrences or metastases. We further compared patients who had tumor progression before or after 60 months. After a median follow-up period of 74.33 months (range 3-329 months), 44 patients (4.9%) had disease recurrence. A total of 38.6% of the recurrences occurred after 60 months; 76.2% of patients had distant metastases and 23.8% of patients had local recurrences. In patients with low-grade (G1) and low-stage (pT1a) tumors, there was a trend to develop recurrence or metastases after longer intervals. Patients with lung metastasis and patients with multiple metastatic locations developed these metastases earlier than patients with bone metastasis. The risk of dying of other causes correlated with age, but the time interval to metastases did not. Current guidelines recommend a follow-up period of 60 months after surgical treatment of organ-confined renal cell carcinoma. Our data shows that one-third of recurrences of <pT3 renal cell carcinoma occur after 60 months. According to our oncological analysis, we suggest an age-adjusted strategy of follow-up balancing the risk of tumor recurrence and the life expectancy of the patient.

Identifiants

pubmed: 30588677
doi: 10.1111/iju.13882
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-390

Informations de copyright

© 2018 The Japanese Urological Association.

Auteurs

Sebastian K Frees (SK)

Department of Urology, University Medical Center, Mainz, Germany.

Mohammed M Kamal (MM)

Department of Urology, University Medical Center, Mainz, Germany.
Urology and Nephrology Center, Mansoura, Egypt.

Sebastian Nestler (S)

Department of Urology, University Medical Center, Mainz, Germany.
Department of Urology, Hochtaunus Hospital Bad Homburg, Bad Homburg, Germany.

Patrick Mf Levien (PM)

Department of Urology, University Medical Center, Mainz, Germany.

Samir Bidnur (S)

Vancouver Prostate Centre, Urological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Walburgis Brenner (W)

Department of Urology, University Medical Center, Mainz, Germany.

Christian Thomas (C)

Department of Urology, University Medical Center, Mainz, Germany.

Wolfgang Jaeger (W)

Department of Urology, University Medical Center, Mainz, Germany.

Joachim W Thüroff (JW)

Department of Urology, University Medical Center, Mainz, Germany.

Frederik C Roos (FC)

Department of Urology, University Medical Center, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH